Rydapt (midostaurin) — CareFirst (Caremark)
Aggressive systemic mastocytosis (ASM)
Initial criteria
- Rydapt is used as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months